Becoming Fundable
Raising capital in life sciences is rarely about the quality of the science. It is about whether investors can clearly underwrite the path from today’s data to a meaningful outcome.
What You May Experience and Why
Capital follows credible pathways, not only promising data
Financing processes in life sciences often begin with confidence. The science is progressing, early investor meetings are constructive, and advisors are supportive. Yet over time, momentum slows.
Meetings go well but do not advance. Feedback varies widely depending on who you speak with. You are asked questions that feel only indirectly related to the biology. You are encouraged to return after the next milestone, without clarity on which milestone will actually change the outcome. Internally, the board may believe the process should be easier than it is.
In most cases, this is not a reflection of weak science. It reflects a difference between what the company is presenting and what investors are evaluating.
Investors are not underwriting data in isolation. They are underwriting a pathway. Clinical risk, regulatory risk, commercial relevance, and execution risk are being assessed simultaneously. Companies present scientific validation. Investors evaluate company viability.
Capital follows credible pathways, not only promising data.
Science → Development Path → Company → Future Buyer or Partner
When that pathway is clear and coherent, financing processes move forward. When it is not, additional data alone rarely resolves hesitation.
How We Evaluate Financing Readiness
Financing outcomes are rarely determined by a single dataset or meeting. They reflect whether investors can see a coherent path from today’s position to a meaningful milestone and who will care about the company at that point.
To make this assessable, we use a structured readiness framework that looks beyond the science and examines how the product, organization, and narrative support a credible financing process.
1
The Asset and Development Path
We assess whether the program represents a credible and fundable opportunity. This includes unmet need, differentiation, and whether the development plan supports a meaningful value inflection point.
Investors are not only asking if the science works, but whether the asset can reach a stage where partners or future investors will care.
2
The Capital Raise Narrative
We evaluate how clearly the company explains why capital is being raised and what changes as a result. This includes alignment between the capital ask, milestones, timelines, and risk as well as expected syndicate governance.
Financing depends on whether stakeholders can see a coherent path from today’s position to a defined outcome.
3
The Organization and Execution
We review whether the company is structured to execute the next stage of development. This includes leadership alignment, decision clarity, and operating readiness.
Many financings stall not because of the asset, but because investors lack confidence in the company having put together the right operating model for execution.
Recent Situations We Have Helped Companies With
Our Insights
Before You Start Your Financing Process
Many companies only seek advice once a financing process has begun. By then, positioning is already anchored. The most productive conversations usually happen before outreach starts.
